The Environment Agency has joined forces with local businesses to reduce the risk of flooding to the community and give wildlife a boost in Teesside.

Work has started on the £11million project, which will increase flood protection from Greatham Creek while creating around 30 hectares of extra habitat.

The Environment Agency is working with local businesses in the area with SABIC UK providing funding towards the scheme and INOVYN ChlorVinyls providing some of their land for the additional habitat creation.

And they are working closely with partners at RSPB and Natural England to design and build a scheme which maximises benefits for the internationally designated habitat, and to ensure disruption to wildlife and visitors to the local area is kept to a minimum.

New habitat creation

The first phase of the project, which saw new flood defences built at Port Clarence to reduce flood risk from the River Tees at a cost of £4.5million, was finished in December 2015.

Phase two will see the Environment Agency raise existing flood embankments along Greatham Creek, to reduce the flood risk to Port Clarence and land which is south of the Creek.

There will also be a managed realignment of part of the current flood defences. This means a new embankment to the north of RSPB Saltholme Nature Reserve will be built around a larger area of land, and then the existing flood embankment will be breached.

This results in the creation of around 30 hectares of intertidal habitat to the north of the nature reserve. It’s a popular area frequented by seals, and a variety of bird species including shelduck, knot and redshank.

Seals at Greatham Creek

Phase 2 is expected to be complete by the end of 2018. Together the projects reduce the risk of flooding from both the River Tees and Greatham Creek at Port Clarence, protecting 350 homes and 32 businesses.

‘Vastly improving existing defences’

The Environment Agency’s Senior Advisor on the scheme Phil Marshall said:

I remember well the devastating impact the tidal surge in December 2013 had on the area, affecting around 50 homes and businesses.

By working together with local industry we’re vastly improving existing defences to protect residents and businesses and reduce the risk of flooding now and into the future as sea levels start to rise.

It’s a great example of how we’re working closely with partners, businesses and communities to create long-term, sustainable solutions to flooding while also making enhancements to the environment.

This is a vital conservation area enjoyed by visitors from far and wide and we’re taking the opportunity to create 30 hectares of extra habitat to ensure wildlife continues to thrive.

In addition, while access to the creek is limited during the work, we are working with RSPB Saltholme to enable visitors to see live images from the creek of the ever popular seals.

Image shows (L) Daren Smith, SABIC site director, and (R) Phil Marshall, Environment Agency Senior Advisor

Working in partnership

Daren Smith, SABIC Site Director (acting) added:

As a responsible company, SABIC take the protection of our environment and our communities extremely seriously. Our own land was devastated by the flood but our employees worked extremely hard and quickly with local agencies to rebuild some of the natural habitats that exist there.

SABIC are delighted to be working in partnership with the Environment Agency and other agencies to enable this vital sustainable project to be delivered.

Contractors BMMJV (BAM Nuttall and Mott MacDonald Joint Venture), are carrying out the work on behalf of the Environment Agency.

Phase 1 of the scheme saw new flood defences built in Port Clarence, consisting of a mixture of earth embankments, flood walls, and a raised section of the road on the approach to the Transporter Bridge.

In addition, the Environment Agency worked together with local business Wilton Engineering to install removable steel flood defences along the River Tees to improve flood protection while still allowing Wilton to operate from the river.

If you would like to know more about your risk of flooding and how to be prepared call Floodline on 0345 988 1188, or visit www.gov.uk/flood

UK businesses can apply for a share of £3 million to work with Chinese partners on challenges faced by cities in Guandong province.

Maloff Protect anti-malaria tablets are now available to buy from pharmacies, after previously only being available to purchase with a prescription.

The news follows a successful public consultation, where members of the public were asked to contribute their say on the availability of the product.

The tablets will be available to adults aged over 18 weighing more than 40kg travelling to areas where malaria is widespread.

Patients must tell their pharmacist which countries they will be visiting: it is essential that to take an antimalarial that will be effective in those areas. You will need to start the tablets before arriving in a malaria-endemic area and to continue taking them for 7 days after leaving.

A final decision was made by MHRA, on behalf of the UK Licensing Authority, after responses from the public consultation were analysed.

Following a stringent assessment procedure, The Commission on Human Medicines (CHM) recommended reclassifying the tablets for those travelling in areas where malaria is common.

MHRA always want to encourage people to be involved in their healthcare and are in the process of holding public consultations for conditions that are suitable for self-care.

Maloff Protect was one of a number of medicines currently being considered for reclassification as an over the counter medicine, to help widen access to medicines for the benefit of public health when it is safe to do.

Every year there are millions of new cases of malaria worldwide and thousands of travellers are diagnosed after returning to the UK, resulting in occasional and tragically avoidable deaths.

The Medicines and Healthcare products Regulatory Agency has today announced the approval of an antimalarial tablet which will be available through pharmacies without prescription.

Sold under the brand name Maloff Protect,l the tablets contain two antimalarial agents, atovaquone and proguanil.

Maloff Protect will be sold at pharmacies after a discussion with the pharmacist. They will be made available to adults aged over 18, weighing more than 40kg, travelling to areas affected by malaria and where the malaria parasite is not resistant to the Maloff Protect ingredients.

Pharmacists will be able to advise if Maloff Protect is suitable to protect from malaria depending on which countries are being visited, pre-existing medical conditions, and any other medicines being taken.

Make sure you tell your pharmacist which countries you will be visiting: it is essential that you take an antimalarial that will be effective in those areas. You will need to start the tablets before arriving in a malaria-endemic area and to continue taking them for 7 days after leaving.

Pharmacists will also be best placed to advise how to avoid mosquito bites, such as the use of bed nets, repellent sprays and appropriate clothing when outside. They will also be able to reinforce the importance of seeking a full travel consultation, including the need for travel vaccinations.

Maloff Protect was one of a number of medicines currently being considered for reclassification as an over the counter medicine, to help widen access to medicines for the benefit of public health when it is safe to do. This reclassification is a result of a public consultation, held earlier this year.

Dr Sarah Branch, MHRA’s Deputy Director of VRMM, said:

Malaria is a very serious disease and taking adequate protection when travelling to malaria infected zones can be life-saving. Today’s move to make another antimalarial more widely available will make it easier to access.

Making more preventative medicines more readily available along with additional healthcare advice for travellers is an important step forward.

A full consultation with a healthcare professional is always recommended before you go to places where malaria is prevalent and pharmacists are well placed to help direct travellers to additional sources of information and information and advice.

Mr Martin Astbury, President of the Royal Pharmaceutical Society, said:

This is great news for both pharmacists and travellers. It means people travelling abroad can access the medicine at their convenience and without a prescription from their GP, which would undoubtedly result in better access to protection from malaria.

Pharmacists already offer a full range of travel advice and in some cases vaccinations. Malaria prevention is a well-established area of expertise for pharmacists and a great opportunity to provide full travel advice to people travelling anywhere in the world.

Pharmacists have access to up to date information and resources and are very well equipped to provide this medicine safely and appropriately. As the professional body for pharmacists, the RPS will be publishing professional guidance on this topic.

Background

1. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe.

2. All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks. MHRA is a centre of the Medicines and Healthcare products Regulatory Agency which also includes NIBSC and CPRD. The Medicines and Healthcare products Regulatory Agency is an executive agency of the Department of Health.

3. Maloff Protect is a medicine to be taken by mouth to prevent malaria infection in adults travelling to areas where malaria is widespread. The active ingredients are atovaquone and proguanil. Both are in a class of drugs called biguanides used to prevent and treat malaria.

4. Per the World Health Organization’s (WHO) 2016 World Malaria Report, there were 212 million new cases of malaria worldwide in 2015. In 2015, there were an estimated 429 000 malaria deaths worldwide. Malaria is not found in the UK, although about 1,586 travelers were diagnosed with the disease after returning to the UK in 2014, and three people died.

5. Following a public consultation, The Commission on Human Medicines (CHM) advised in favour of Pharmacy availability of Maloff Protect. The CHM is an advisory non-departmental public body, sponsored by the Department of Health that advises ministers on the safety, efficacy and quality of medicinal products.

6. Maloff Protect has been reclassified from a prescription only medicine to one available in pharmacies. Pharmacists are experts in medicine, and have the necessary skills and training to ensure the safe and efficient supply of pharmacy medicines. The link to the public consultation is here:

7. MHRA involved the public and healthcare professionals throughout the decision-making process. We carefully analysed their contribution in the public consultation phases before deciding how to proceed. The responses to the consultation were predominantly positive. Full set of consultation responses can be seen here:

8. People travelling should also look at: http://nathnac.net/ and http://www.travax.nhs.uk/ (for Scotland) Other sites include PHE’s Advisory Committee on Malaria Prevention updates which are issued annually:, NICE guidance and the [NHS choices site] (http://www.nhs.uk/Conditions/Malaria/Pages/Prevention.aspx).